scholarly journals Correlation between Interleukin-4 Gene Promoter Polymorphisms with Thyrotropin Receptor Antibody and Transforming Growth Factor-β

2020 ◽  
Vol 8 (A) ◽  
pp. 793-796
Author(s):  
Raveinal Raveinal ◽  
Eryati Darwin ◽  
Eva Decroli ◽  
Jamsari Jamsari
Keyword(s):  
Transforming Growth Factor ◽  
Gene Promoter ◽  
Transforming Growth Factor Β ◽  
Interleukin 4 ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Wild Type ◽  
Promoter Polymorphisms ◽  
Thyrotropin Receptor Antibody ◽  
The Mean

AIM: The aim of this study was to determine the correlation between interleukin-4 (IL-4) gene promoter polymorphisms with thyrotropin receptor antibody (TRAb) and transforming growth factor-β (TGF-β). METHODS: This study was conducted from August 2015 until December 2015 in the internal medicine department in Dr. M. Djamil Hospital, Padang, West Sumatera, Indonesia. Graves’ disease was confirmed by measuring free thyroxine, thyroid-stimulating hormone, and TRAb. We examined that IL-4 promotor gene polymorphism was examined with a polymerase chain reaction. Graves’ disease serum patients will be used to check levels of TGFβ and TRAb antibodies using the enzyme-linked immunoassay method. RESULTS: There are 15 patients in this study. The average of age in patients group is 40.87 (11.23) years. The number of female patients in this study is more than male patients, with the percentage of women are 73.3%, and men are 26.7%. The sequencing examination on IL-4 gene promoter resulted in 2 single nucleotide polymorphism motifs, which are rs2243250 and rs2070847. The mean TRAb level in wild type and mutant group is 6.77 (5.73) IU/L and 4.66 (3.91) IU/L, respectively. The mean TGF-β levels in wild type and mutant group are 1168.89 (438.91) pg/mL and 1114.79 (296.02) pg/mL, respectively. Statistical tests showed no association between IL-4 gene promoter polymorphisms with TRAb and TGF-β levels (p > 0.05). CONCLUSION: There is no correlation between IL-4 gene promoter polymorphisms with TRAb and TGF-β.

scholarly journals THE ROLE OF INTERLEUKIN-4 GENE PROMOTER POLYMORPHISMS IN GRAVES’ DISEASE

2020 ◽  
pp. 73-75
Author(s):  
RAVEINAL RAVEINAL ◽  
ERYATI DARWIN ◽  
EVA DECROLI ◽  
JAMSARI JAMSARI
Keyword(s):  
Statistical Tests ◽  
Gene Promoter ◽  
Normal Subjects ◽  
Promoter Polymorphism ◽  
Interleukin 4 ◽  
Control Group ◽  
Graves Disease ◽  
Promoter Polymorphisms ◽  
And Control

Objective: This study was conducted to prove the role of interleukin-4 gene promoter polymorphisms in Graves’ disease patients in M Djamil General Hospital Padang, Indonesia. Methods: This study was conducted from August 2015 until December 2015 in the Internal Medicine Department in Dr. M. Djamil Hospital, Padang, West Sumatera, Indonesia. This study involved 15 patients with Graves’ disease and 15 normal subjects. We examined that IL-4 promoter gene polymorphism was examined with PCR. Results: Sequencing examination on IL-4 gene promoter resulted in 2 Single Nucleotide Polymorphism (SNP) motifs, which is rs2243250 and rs2070847. IL-4 SNP gene promoter polymorphisms rs2243250 and rs2070847 were found in both patient and control groups. TT is homozygous SNP polymorphisms. CT is heterozygous SNP polymorphisms. CC is wild type or no mutation SNP polymorphisms. Based on statistical tests, no difference in rs2243250 and rs2070847 SNP polymorphisms was found between patient and control group (p > 0.05). Conclusion: This study observed no difference in interleukin-4 gene promoter polymorphism between Graves’ disease patients and control group.

scholarly journals Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis

Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1084
Author(s):  
Junya Ono ◽  
Masayuki Takai ◽  
Ayami Kamei ◽  
Yoshinori Azuma ◽  
Kenji Izuhara
Keyword(s):  
Pulmonary Fibrosis ◽  
Transforming Growth Factor ◽  
Biological Fluids ◽  
Allergic Inflammation ◽  
Transforming Growth Factor Β ◽  
Serum Levels ◽  
Vital Role ◽  
Interleukin 4 ◽  
Type 2 Inflammation

Periostin is known to be a useful biomarker for various diseases. In this article, we focus on allergic diseases and pulmonary fibrosis, for which we and others are now developing detection systems for periostin as a biomarker. Biomarker-based precision medicine in the management of type 2 inflammation and fibrotic diseases since heterogeneity is of utmost importance. Periostin expression is induced by type 2 cytokines (interleukin-4/-13) or transforming growth factor-β, and plays a vital role in the pathogenesis of allergic inflammation or interstitial lung disease, respectively, andits serum levels are correlated disease severity, prognosis and responsiveness to the treatment. We first summarise the importance of type 2 biomarker and then describe the pathological role of periostin in the development and progression of type 2 allergic inflammation and pulmonary fibrosis. In addition, then, we summarise the recent development of assay methods for periostin detection, and analyse the diseases in which periostin concentration is elevated in serum and local biological fluids and its usefulness as a biomarker. Furthermore, we describe recent findings of periostin as a biomarker in the use of biologics or anti-fibrotic therapy. Finally, we describe the factors that influence the change in periostin concentration under the healthy conditions.

scholarly journals Gender Is a Major Determinant of the Clinical Evolution and Immune Response in Hamsters Infected with Leishmania spp.

2002 ◽  
Vol 70 (5) ◽  
pp. 2288-2296 ◽  
Author(s):  
Bruno L. Travi ◽  
Yaneth Osorio ◽  
Peter C. Melby ◽  
Bysani Chandrasekar ◽  
Lourdes Arteaga ◽  
...  
Keyword(s):  
Immune Response ◽  
Transforming Growth Factor ◽  
Experimental Studies ◽  
Parasite Burden ◽  
Transforming Growth Factor Β ◽  
Lesion Size ◽  
Interleukin 4 ◽  
Cutaneous Lesions ◽  
Disease Evolution ◽  
Leishmania Spp

ABSTRACT In regions where leishmaniasis is endemic, clinical disease is usually reported more frequently among males than females. This difference could be due to disparate risks of exposure of males and females, but gender-related differences in the host response to infection may also play a role. Experimental studies of the influence of gender on Leishmania infection have not included parasites of the subgenus Viannia, which is the most common cause of cutaneous leishmaniasis in the Americas. Mice are not readily susceptible to infection by Leishmania (Viannia) spp., but cutaneous infection of hamsters with L. (V.) panamensis or L. (V.) guyanensis resulted in chronic lesions typical of the human disease caused by these parasites. Strikingly, infection of male hamsters resulted in significantly greater lesion size and severity, an increased rate of dissemination to distant cutaneous sites, and a greater parasite burden in the draining lymph node than infection in female animals. Two lines of evidence indicated this gender-related difference in disease evolution was determined at least in part by the sex hormone status of the animal. First, prepubertal male animals had smaller and/or less severe cutaneous lesions than adult male animals. Second, infection of testosterone-treated female animals resulted in significantly larger lesions than in untreated female animals. The increased severity of disease in male compared to female animals was associated with significantly greater intralesional expression of interleukin-4 (IL-4) (P = 0.04), IL-10 (P = 0.04), and transforming growth factor β (TGF-β) (P < 0.001), cytokines known to promote disease in experimental leishmaniasis. There was a direct correlation between the expression of TGF-β mRNA and lesion size (Spearman's correlation coefficient = 0.873; P < 0.001). These findings demonstrate an inherent risk of increased disease severity in male animals, which is associated with a more permissive immune response.

scholarly journals Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease

1998 ◽  
pp. 281-285 ◽  
Author(s):  
M Akuzawa ◽  
M Murakami ◽  
M Yamada ◽  
T Satoh ◽  
H Shimizu ◽  
...  
Keyword(s):  
Thyroid Function ◽  
Normal Subjects ◽  
Term Treatment ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Receptor Antibody ◽  
Thyrotropin Receptor Antibody ◽  
Long Term Treatment ◽  
Tsh Levels

Clinical evaluation was conducted to ascertain whether thyrotropin receptor antibody (TRAb) in the normal range may still be involved in the regulation of thyroid function after prolonged treatment for Graves' disease. All patients (n = 33) were treated with antithyroid drugs for an average of 10.6 years and were under euthyroid conditions in which normal blood levels of tri-iodothyronine (T3) were significantly correlated with blood thyrotropin (TSH) levels, but not with titers of TRAb. A significant correlation was observed between TRAb titer and thyroid-stimulating antibody (TSAb) activity. In contrast, this correlation was not found in normal subjects. After administration of T3 (75 microg daily for 8 days), the patients showed increased levels of T3 with concomitant suppression of TSH levels. Under these conditions, linear regression analysis showed significant correlations of TRAb titer and TSAb activity with 24-h thyroid radioiodine uptake (r = 0.641 and 0.621 respectively, P < 0.01), in contrast to declining blood thyroxine levels. Moreover, the immunoglobulin G (IgG) of the patients precipitated to a greater extent than IgG from normal subjects a peptide consisting of the amino acid sequence near the terminus of the human TSH receptor. These findings indicated that TRAb at normal levels possessed significant unremitting activities on thyroid function despite long-term treatment in euthyroid patients with Graves' disease.

scholarly journals TAK1 deficiency attenuates cisplatin-induced acute kidney injury

2020 ◽  
Vol 318 (1) ◽  
pp. F209-F215 ◽  
Author(s):  
Jun Zhou ◽  
Changlong An ◽  
Xiaogao Jin ◽  
Zhaoyong Hu ◽  
Robert L. Safirstein ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Proximal Tubule ◽  
Molecular Mechanisms ◽  
Transforming Growth Factor ◽  
Kidney Injury ◽  
Transforming Growth Factor Β ◽  
Tubular Epithelial Cell ◽  
Tubular Damage ◽  
Wild Type ◽  
Deficient Mice

Cisplatin can cause acute kidney injury (AKI), but the molecular mechanisms are not well understood. The objective of the present study was to examine the role of transforming growth factor-β-activated kinase-1 (TAK1) in the pathogenesis of cisplatin-induced AKI. Wild-type mice and proximal tubule TAK1-deficient mice were treated with vehicle or cisplatin. Compared with wild-type control mice, proximal tubule TAK1-deficient mice had less severe kidney dysfunction, tubular damage, and apoptosis after cisplatin–induced AKI. Furthermore, conditional disruption of TAK1 in proximal tubular epithelial cells reduced caspase-3 activation, proinflammatory molecule expression, and JNK phosphorylation in the kidney in cisplatin-induced AKI. Taken together, cisplatin activates TAK1-JNK signaling pathway to promote tubular epithelial cell apoptosis and inflammation in cisplatin-induced AKI. Targeting TAK1 could be a novel therapeutic strategy against cisplatin-induced AKI.

Inhibition of Lymphocyte Adherence to Rat Lacrimal Acinar Epithelium by Interleukin-4 and Transforming Growth Factor-β

1994 ◽  
Vol 153 (1) ◽  
pp. 154-162 ◽  
Author(s):  
Mohamed G. Elfaki ◽  
Nancy L. O'Sullivan ◽  
Cheryl A. Skandera ◽  
Paul C. Montgomery
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Interleukin 4

scholarly journals Activin βC and βE Genes Are Not Essential for Mouse Liver Growth, Differentiation, and Regeneration

2000 ◽  
Vol 20 (16) ◽  
pp. 6127-6137 ◽  
Author(s):  
Anthony L. Lau ◽  
T. Rajendra Kumar ◽  
Katsuhiko Nishimori ◽  
Jeffrey Bonadio ◽  
Martin M. Matzuk
Keyword(s):  
Embryonic Development ◽  
Transforming Growth Factor ◽  
Serum Proteins ◽  
Embryonic Stem ◽  
Transforming Growth Factor Β ◽  
Wild Type ◽  
Rnase Protection ◽  
Liver Growth ◽  
Adult Mice ◽  
The Individual

ABSTRACT The liver is an essential organ that produces several serum proteins, stores vital nutrients, and detoxifies many carcinogenic and xenobiotic compounds. Various growth factors positively regulate liver growth, but only a few negative regulators are known. Among the latter are the transforming growth factor β (TGF-β) superfamily members TGF-β1 and activin A. To study the function of novel activin family members, we have cloned and generated mice deficient in the activin βC and βE genes. Expression analyses demonstrated that these novel genes are liver specific in adult mice. Here, we show by RNase protection that activin βC transcripts are present in the liver beginning at embryonic day 11.5 (E11.5) whereas activin βE expression is detected starting from E17.5. Gene targeting in embryonic stem cells was used to generate mice with null mutations in either the individual activin βC and βE genes or both genes. In contrast to the structurally related activin βA and βB subunits, which are necessary for embryonic development and pituitary follicle-stimulating hormone homeostasis, mice deficient in activin βC and βE were viable, survived to adulthood, and demonstrated no reproductive abnormalities. Although activin βC and βE mRNAs are abundantly expressed in the liver of wild-type mice, the single and double mutants did not show any defects in liver development and function. Furthermore, in the homozygous mutant mice, liver regeneration after >70% partial hepatectomy was comparable to that in wild-type mice. Our results suggest that activin βC and βE are not essential for either embryonic development or liver function.

scholarly journals Orally Administered Mycobacterium vaccae Modulates Expression of Immunoregulatory Molecules in BALB/c Mice with Pulmonary Tuberculosis

2008 ◽  
Vol 15 (11) ◽  
pp. 1730-1736 ◽  
Author(s):  
Rogelio Hernández-Pando ◽  
Diana Aguilar ◽  
Hector Orozco ◽  
Yuriria Cortez ◽  
Laura Rosa Brunet ◽  
...  
Keyword(s):  
T Cells ◽  
Pulmonary Tuberculosis ◽  
Oral Administration ◽  
Subcutaneous Injection ◽  
Transforming Growth Factor ◽  
Cytotoxic T Cells ◽  
Transforming Growth Factor Β ◽  
Interleukin 4 ◽  
High Dose ◽  
Mycobacterium Vaccae

ABSTRACT The environmental saprophyte Mycobacterium vaccae induces a Th1 response and cytotoxic T cells that recognize M. tuberculosis, and by subcutaneous injection, it is therapeutic for pulmonary tuberculosis (TB) induced by high-dose challenge in BALB/c mice. However, M. vaccae also drives regulatory T cells that inhibit Th2 responses, and this is seen in allergy models, not only following subcutaneous injection but also after oral administration. An oral immunotherapeutic for TB would be clinically useful, so we investigated M. vaccae given orally by gavage at 28-day intervals in the TB model. We used two different protocols: starting the oral M. vaccae either 1 day before or 32 days after infection with M. tuberculosis. Throughout the infection (until 120 days), we monitored outcome (CFU), molecules involved in the development of immunoregulation (Foxp3, hemoxygenase 1, idoleamine 2,3-dioxygenase, and transforming growth factor β [TGF-β]), and indicators of cytokine balance (tumor necrosis factor, inducible nitric oxide synthase, interleukin-4 [IL-4], and IL-4δ2; an inhibitory splice variant of IL-4 associated with improved outcome in human TB). Oral M. vaccae had a significant effect on CFU and led to increased expression of Th1 markers and of IL-4δ2, while suppressing IL-4, Foxp3, and TGF-β. When administered 1 day before infection, oral M. vaccae induced a striking peak of expression of hemoxygenase 1. In conclusion, we show novel information about the expression in TB of murine IL-4δ2 and molecules involved in immunoregulation and show that these can be modulated by oral administration of a saprophytic mycobacterium. A clinical trial of oral M. vaccae in extensively drug-resistant TB might be justified.

Sign in / Sign up

Export Citation Format

Share Document